Cefoperazone-sulbactam plus amikacin empirical therapy for febrile neutropenia in children with cancer
Aim: To determine the efficacy and safety of cefoperazone-sulbactam combined with amikacin in the treatment of febrile neutropenia in children with cancer. Materials and Methods: The study included 20 cancer cases with 26 febrile neutropenia (FEN) episodes. Patient selection criteria were defined according to the guidelines issued by the Infectious Disease Society of America (IDSA). Results: Patients diagnosed with acute leukemia (58%) and solid tumors (42%) were recorded. Twelve (46.2%) of the primary disease cases were refractory. The number of infection episodes identified microbiologically and clinically was 10 (38.5%) and 12 (46.1%), respectively. Fever of unknown origin was observed in only 4 cases (15.4%). The success rate of the empirical treatment without additional modification was 42.3% (11 FEN episodes). Four episodes (15.4%) needed a replacement for sulbactam/cefoperazone because of persistent fever, adverse reactions, and/or clinical deterioration. Three patients died because of relapse or because they were refractory. As 15 (57.7%) of the patients deteriorated clinically and had fever, glycopeptide antibiotics were given after 48-72 h. The overall response rate at the end of the therapy was 80.8%, with/without modification. Conclusions: The combination of sulbactam/cefoperazone plus amikacin was effective and safe in the treatment of febrile episodes in neutropenic pediatric cancer patients.
Anahtar Kelimeler:
Key words: Neutropenic fever, childhood, cefoperazone/sulbactam, amikacin
Cefoperazone-sulbactam plus amikacin empirical therapy for febrile neutropenia in children with cancer
Aim: To determine the efficacy and safety of cefoperazone-sulbactam combined with amikacin in the treatment of febrile neutropenia in children with cancer. Materials and Methods: The study included 20 cancer cases with 26 febrile neutropenia (FEN) episodes. Patient selection criteria were defined according to the guidelines issued by the Infectious Disease Society of America (IDSA). Results: Patients diagnosed with acute leukemia (58%) and solid tumors (42%) were recorded. Twelve (46.2%) of the primary disease cases were refractory. The number of infection episodes identified microbiologically and clinically was 10 (38.5%) and 12 (46.1%), respectively. Fever of unknown origin was observed in only 4 cases (15.4%). The success rate of the empirical treatment without additional modification was 42.3% (11 FEN episodes). Four episodes (15.4%) needed a replacement for sulbactam/cefoperazone because of persistent fever, adverse reactions, and/or clinical deterioration. Three patients died because of relapse or because they were refractory. As 15 (57.7%) of the patients deteriorated clinically and had fever, glycopeptide antibiotics were given after 48-72 h. The overall response rate at the end of the therapy was 80.8%, with/without modification. Conclusions: The combination of sulbactam/cefoperazone plus amikacin was effective and safe in the treatment of febrile episodes in neutropenic pediatric cancer patients.
Keywords:
Key words: Neutropenic fever, childhood, cefoperazone/sulbactam, amikacin,
___
- Özyılkan Ö, Yalçıntaş Ü, Başkan S. Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients. The Korean J Internal Medicine 1999; 14: 15-19.
- Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Ca- landra T et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Infectious Diseases Soci- ety of America. Clin Infect Dis 2002; 34: 730-751.
- Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis 2002; 15: 377-482.
- Winston DJ, Bartoni K, Bruckner DA, Schiller GJ, Territo MC. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocy- topenic patients. CID 1998; 26: 576-583.
- El Haddad AMA. Comparison of cefoperazone-sulbactam ver- sus piperacillin plus amikacin as empiric therapy in pediatric febrile neutropenic cancer patients. Cur Ther Res 1995; 56: 1094-1099.
- Horiuchi A, Hasegawa H, Kageyama T, Yonezawa T, Kitani T, Masaoka T et al. Efficacy of sulbactam/cefoperazone for the treatment of infections in patients with hematologic diseases. Diagn Microbiol Infect Dis 1989; 12: 215-219.
- Takemoto Y, Kanamaru A, Kakishita E, Nakayama S, Hara H, Yamaguchi N et al. An evaluation of combination antibiotic therapy in infections with hematological disorders. Hyogo co- operative study group of Infectious Diseases Complicating He- motological Disorders. Jpn J Antibiot 1991; 44: 296-302.
- Bodey G, Abi-Said D, Rolston K, Raad I, Whimbey E. Imipenem or cefoperazone-sulbactam combined with van- comycin for therapy of presumed or proven infection in neu- tropenic cancer patients. Eur J Microbiol Infect Dis 1996; 15: 625-634.
- Afanas’ev BV, Zubarevskaia LS, Shmdt AV, Zabelina TS. Expe- rience with using cefoperazone in cancer patients after bone marrow transplantation. Antidit Khimioter 1992; 37: 14-15.
- Bickers J, Gumbart C, Vial R, Veith R, McCormick, Fussell S et al. A prospective randomized trial of cefoperazone plus sulbac- tam versus imipenem-cilastatin in febrile neutropenic patients (abstract 569). In: Program and abstracts of the 18th Interna- tional Congress of Chemotherapy (Stockholm) 1993: 217.
- Mitrokhin SD. Sulperazone in the treatment of severe infections in patients with cancer. Antibiot Khimioter 2003; 48: 26-29.
- ISSN: 1300-0144
- Yayın Aralığı: Yılda 6 Sayı
- Yayıncı: TÜBİTAK
Sayıdaki Diğer Makaleler
Comparison of outcomes of percutaneous nephrolithotomy on patients with normal and malformed kidneys
Bayram DOĞAN, Ahmet Tunç ÖZDEMİR, Ege Can ŞEREFOĞLU, M. Derya BALBAY, Ali Fuat ATMACA, Abdullah Erdem CANDA
Coxiella burnetii seroprevalence in the rural part of Bolu, Turkey
Oğuz KARABAY, Gökhan BAYSOY, Selami KONYALIOĞLU, Esra KOCOĞLU
Hasan Rıza AYDIN, İsa ÖZBEY, Yılmaz AKSOY, Turgut YAPANOĞLU
Murat KURT, Canan ÇULHA, Hakan TUNÇ, Ünsal Sibel DELİALİOĞLU, Ali ATAN, Sumru ÖZEL
Baş boyun bölgesi skuamöz hücreli karsinomunda anneksin A2, A7 ve A11 in ekspresyonları
Erdem KARABULUT, Bülent ÖCAL, Murat ALPER, Berrak GÜMÜŞKAYA, Sema HÜCÜMENOĞLU
Measurement of total antioxidant response in colorectal cancer using a novel automated method
Ali UZUNKÖY, Fuat DİLMEÇ, Nurten AKSOY, Abdullah ÖZGÖNÜL, Şahin AKSOY
Radiological and pathological correlation in patients with bronchioloalveolar lung carcinoma
İlker ETİKAN, Funda DEMİRAĞ, Serpil ÖCAL, Belgin SAMURKAŞOĞLU, Pelin BAYAZIT, Önde Gülnur ÜÇOLUK
Clinical evaluation of 625 lacunar syndrome patients
Kavian GHANDEHARI, Zahra IZADI
Increased P wave dispersion in hypothyroidism: a sign of risk of atrial fibrillation
Cemil BİLİR, Hakan CİNEMRE, Ramazan AKDEMİR, Harun KILIÇ, Ebru Neslihan ERYAŞARA, Kudret ÇELİK, Aşkın GÜNGÜNEŞ, Nermin AKDEMİR